A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes

15244BAYER-FINEONEOpen (affiliates only)A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetesIndustrialAdultTreatmentType 1 Diabetes MellitusPark, JeanMedStar Community Clinical Research Center; MedStar Community Clinical Research Center - Hyattsville; MedStar Medical Group - Hyattsville ClinicMHRI Community Research2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>